Information Provided By: 
Fly News Breaks for August 8, 2017
HZNP
Aug 8, 2017 | 08:59 EDT
UBS analyst Marc Goodman noted Horizon Pharma shares were up only 5% after a big beat and raise quarter. He said investors pushed back on the smaller than expected increase in guidance and the concerns around Krystexxa pricing. The analyst believes management is being very conservative with numbers but still sees sales better in the second half 2017. Goodman reiterated his Buy rating and $16 price target on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
